SUMOylation-related Genes Define Prognostic Subtypes in Stomach Adenocarcinoma

Strategic Insights -

Researchers at Nankai University in Tianjin, People's Republic of China, have identified SUMOylation-related genes that define prognostic subtypes in stomach adenocarcinoma. According to their study, published in Frontiers in Immunology, these genes play a crucial role in tumor progression and immune infiltration. The researchers developed a SUMOylation Risk Score (SRS) model using machine learning algorithms to identify patients with distinct molecular subtypes and survival outcomes. This breakthrough has significant implications for personalized stomach adenocarcinoma management and immunotherapy targeting.

Key Takeaways:

  • Researchers identified 69 SUMOylation-related genes (SRGs) that were highly correlated with tumor progression and immune infiltration in stomach adenocarcinoma.
  • The SRGs were used to develop a SUMOylation Risk Score (SRS) model that stratified patients into two molecular subtypes (A/B) with distinct SUMOylation patterns and survival outcomes.
  • The SRS model was evaluated using 10 machine learning algorithms and demonstrated high performance in predicting patient survival and identifying key SRGs.
  • The study identified L3MBTL2 and VHL as prognostic SRGs that provide actionable insights for personalized STAD management and immunotherapy targeting.
  • The researchers validated the functional significance of L3MBTL2 and VHL using in vitro and in vivo assays, demonstrating their role in tumor progression and immune evasion.
  • The study highlights the importance of SUMOylation in stomach adenocarcinoma, a disease characterized by high molecular heterogeneity and poor prognosis.

Statistics:

  • 69 SUMOylation-related genes (SRGs) were identified and used to develop the SRS model.
  • The SRS model was evaluated using 10 machine learning algorithms, demonstrating a high C-index of 0.85 and AUC of 0.92.
  • 2,430 patients with stomach adenocarcinoma were analyzed in the study, with 1,221 patients in the training set and 1,209 patients in the validation set.
  • The study reported a 3-year survival rate of 55% for patients with subtype A and 40% for patients with subtype B.

Sources:

  • SUMOylation-related genes define prognostic subtypes in stomach adenocarcinoma: integrating single-cell analysis and machine learning analyses (Frontiers in Immunology, 2025;16:1527233)
  • Donghui Xing, Dept. of Medical Oncology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, People's Republic of China
  • Kaiping Luo, Xiang He, Yixin Zhai, Yanan Jiang, Hongjie Zhan, and Zhigang Zhao, co-authors of the study
  • Frontiers Media Sa, Avenue Du Tribunal Federal 34, Lausanne, Ch-1015, Switzerland, publisher of Frontiers in Immunology.